Agreement for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.). Medicare coverage now totals 32 million Medicare lives in the U.S. (58% of approximately 55 million Medicare lives in the U.S.).

Total commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of approximately 314 million total U.S. lives). Previously, Tonix announced commercial payer agreements with two leading group purchasing organizations, and one major managed Medicare agreement. In addition, TONMYA is covered by Medicaid in nearly all states.

"The second major managed Medicare agreement expands patient access to TONMYA, the first fibromyalgia treatment approved in over 15 years," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. "We believe the commercial and managed Medicare coverage agreements reflect TONMYA’s compelling value to patients and payers as a first-in-class, non-opioid analgesic designed for daily bedtime administration and long-term use in adults with fibromyalgia."

Thomas Englese, MBA, Chief Commercial Officer of Tonix Pharmaceuticals, added, "We remain confident in the trajectory of the TONMYA launch. Our team is focused on executing our strategy across market access, sales, and marketing to improve access for TONMYA and raise awareness for fibromyalgia and TONMYA. This new Medicare coverage agreement is expected to increase patient access to TONMYA. Approximately 50 new sales force representatives have been fully activated in the field, bringing the total sales force to 150 representatives. We are focused on translating the new coverage into more opportunities for fibromyalgia patients to access TONMYA."